desipramine has been researched along with duloxetine in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alfinito, P; Bray, J; Cohn, ST; Deecher, DC; Fensome, A; Johnston, G; Koury, E; Mahaney, PE; Marella, MA; McComas, CC; Nogle, L; Trybulski, EJ; Vu, AT; Ye, F; Zhang, P | 1 |
| Bray, JA; Cohn, ST; Deecher, DC; Dooley, R; Goljer, I; Johnston, GH; Leiter, J; Mahaney, PE; Moore, WJ; Terefenko, EA; Trybulski, EJ; Vu, AT; Zhang, P | 1 |
| Bray, JA; Cohn, ST; Cosmi, SA; Deecher, DC; Harrison, JE; Johnston, GH; Kennedy, JD; Kim, CY; Koury, EJ; Leventhal, L; Mahaney, PE; Smith, VA; Trybulski, EJ; Vu, AT; Whiteside, GT; Zhang, P | 1 |
| Burroughs, K; Cosmi, S; Deecher, DC; Ho, D; Johnston, G; Leiter, J; Mahaney, PE; Sabatucci, JP; Trybulski, E; Zhang, Y | 1 |
| Altenbach, RJ; Black, LA; Brioni, JD; Carr, TL; Cowart, MD; Garrison, TR; Honore, P; Hsieh, GC; Manelli, AM; Marsh, KC; Strakhova, MI; Wensink, EJ; Wetter, JM | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for desipramine and duloxetine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for desipramine and duloxetine
| Article | Year |
|---|---|
Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.
Topics: Humans; Indoles; Molecular Structure; Neurotransmitter Uptake Inhibitors; Norepinephrine; Stereoisomerism; Structure-Activity Relationship | 2008 |
3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.
Topics: Adrenergic Uptake Inhibitors; Animals; Chemistry, Pharmaceutical; Dogs; Dopamine Plasma Membrane Transport Proteins; Drug Design; Humans; Inhibitory Concentration 50; Ligands; Models, Chemical; Norepinephrine; Propanolamines; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship | 2009 |
1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.
Topics: Animals; Body Temperature Regulation; Female; Indoles; Magnetic Resonance Spectroscopy; Neurotransmitter Uptake Inhibitors; Norepinephrine Plasma Membrane Transport Proteins; Pain; Propanolamines; Rats; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship | 2010 |
Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.
Topics: Animals; Crystallography, X-Ray; Ethylamines; Humans; Molecular Conformation; Neurotransmitter Uptake Inhibitors; Norepinephrine; Piperazines; Rats; Structure-Activity Relationship; Thiophenes | 2010 |
Diaryldiamines with dual inhibition of the histamine H(3) receptor and the norepinephrine transporter and the efficacy of 4-(3-(methylamino)-1-phenylpropyl)-6-(2-(pyrrolidin-1-yl)ethoxy)naphthalen-1-ol in pain.
Topics: Animals; Histamine H3 Antagonists; Naphthols; Norepinephrine Plasma Membrane Transport Proteins; Osteoarthritis; Pain; Pyrrolidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2010 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |